| Code | CSB-RA004847MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of PSB114 (also reported as QLP2117 in China), targeting CCR8 (C-C motif chemokine receptor 8)—a chemokine receptor that marks a highly immunosuppressive subset of tumor-infiltrating regulatory T cells (Tregs) within the tumor microenvironment. CCR8⁺ Tregs are associated with potent local immune suppression, and CCR8-directed approaches are used to interrogate how selective modulation of tumor-associated Tregs can restore anti-tumor T-cell activity and reshape the immune contexture in solid tumor models.
PSB114 is described as a glycoengineered / ADCC-enhanced anti-CCR8 IgG1 designed to selectively deplete CCR8⁺ tumor-associated Tregs (and has also been presented as blocking CCL1-mediated CCR8 biology) to enhance anti-tumor immunity, including potential synergy with checkpoint inhibitors. This biosimilar provides the antibody component alone, enabling researchers to investigate CCR8 target biology, Fc-effector–dependent Treg depletion mechanisms (ADCC/ADCP), and downstream functional outcomes (e.g., CD8⁺ T-cell restoration) in controlled experimental systems—supporting assay development and mechanistic studies relevant to CCR8-targeted immuno-oncology strategies.
There are currently no reviews for this product.